Independent perspectives on osteoarthritis development.

Pipeline

Feb 2026 · 14 min

The Current Knee OA Pipeline: What Recent Programmes Tell Us About Development Strategy

Patterns across recent symptom- and structure-modifying programmes and the questions they raise for the next generation of assets.

Biomarkers

Feb 2026 · 9 min

Why a Biomarker Is Only Useful Within a Defined Context of Use

Analytical validity is necessary but never sufficient. A framework for moving from candidate marker to development utility.

Precision OA

Jan 2026 · 12 min

Building a Theratype Hypothesis for an Osteoarthritis Trial

Constructing intervention-specific responder hypotheses that can be tested, refined and defended.

Clinical development

Jan 2026 · 10 min

Pain, Structure or Both? Defining the Development Objective

Aligning the primary claim, endpoint hierarchy and trial duration with the mechanism of action.

Clinical development

Dec 2025 · 13 min

What a Negative Phase II Trial Can Still Teach You

How to separate a failed mechanism from a trial that could not test it — and what to do next.

Imaging

Dec 2025 · 11 min

Designing an Imaging Strategy Around the Mechanism of Action

Selecting modalities, central reading and quantitative readouts based on therapeutic hypothesis and trial phase.

Biology

Nov 2025 · 10 min

The Metabolic Osteoarthritis Opportunity

Where metabolic biology meets joint disease — and what it implies for population strategy and endpoints.

Regulation

Nov 2025 · 12 min

Gene and Cell Therapy in Knee OA: Development Questions That Cannot Be Deferred

Dose, delivery, durability, immunogenicity and long-term follow-up — the questions regulators will ask.

Investment

Oct 2025 · 8 min

From Scientific Advisory Board to Development Decision

How to convert expert opinion into recommendations that withstand investor and regulatory scrutiny.